Aisling Capital Management LP: 13F holdings
CIK 17667212026Q2
| Positions | 14 |
|---|
| Reported value | $471.6m |
|---|
| Filed | 2026-08-13 |
|---|
Change since last quarter
| Positions | 14 (+1 vs prior quarter) |
|---|
| Reported value | $471.6m (-1.0%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| BBIO BRIDGEBIO PHARMA INC | 4,589,611 | $341.8m | 72.5% |
| GLUE MONTE ROSA THERAPEUTICS INC | 1,555,664 | $37.6m | 8.0% |
| SNDX SYNDAX PHARMACEUTICALS INC | 1,316,806 | $28.8m | 6.1% |
| CMPS COMPASS PATHWAYS PLC | 1,432,336 | $20.3m | 4.3% |
| BCAX BICARA THERAPEUTICS INC | 568,919 | $16.9m | 3.6% |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 1,018,018 | $7.8m | 1.6% |
| SRRK SCHOLAR ROCK HLDG CORP | 77,031 | $4.2m | 0.9% |
| UROGEN PHARMA LTD | 108,000 | $4.0m | 0.8% |
| BMEA BIOMEA FUSION INC | 2,048,757 | $3.0m | 0.6% |
| ACRS ACLARIS THERAPEUTICS INC | 434,455 | $2.3m | 0.5% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1766721")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples